Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1XGI

AmpC beta-lactamase in complex with 3-(3-nitro-phenylsulfamoyl)-thiophene-2-carboxylic acid

Summary for 1XGI
Entry DOI10.2210/pdb1xgi/pdb
Related1KE4 1L2S 1XGJ
DescriptorBeta-lactamase, 3-{[(3-NITROANILINE]SULFONYL}THIOPHENE-2-CARBOXYLIC ACID (3 entities in total)
Functional Keywordsampc, beta-lactamase, cephalosporinase, serine hydrolase, hydrolase
Biological sourceEscherichia coli
Cellular locationPeriplasm: P00811
Total number of polymer chains2
Total formula weight79504.16
Authors
Tondi, D.,Morandi, F.,Bonnet, R.,Costi, M.P.,Shoichet, B.K. (deposition date: 2004-09-17, release date: 2005-05-03, Last modification date: 2023-08-23)
Primary citationTondi, D.,Morandi, F.,Bonnet, R.,Costi, M.P.,Shoichet, B.K.
Structure-based optimization of a non-beta-lactam lead results in inhibitors that do not up-regulate beta-lactamase expression in cell culture.
J.Am.Chem.Soc., 127:4632-4639, 2005
Cited by
PubMed Abstract: Bacterial expression of beta-lactamases is the most widespread resistance mechanism to beta-lactam antibiotics, such as penicillins and cephalosporins. There is a pressing need for novel, non-beta-lactam inhibitors of these enzymes. One previously discovered novel inhibitor of the beta-lactamase AmpC, compound 1, has several favorable properties: it is chemically dissimilar to beta-lactams and is a noncovalent, competitive inhibitor of the enzyme. However, at 26 microM its activity is modest. Using the X-ray structure of the AmpC/1 complex as a template, 14 analogues were designed and synthesized. The most active of these, compound 10, had a K(i) of 1 microM, 26-fold better than the lead. To understand the origins of this improved activity, the structures of AmpC in complex with compound 10 and an analogue, compound 11, were determined by X-ray crystallography to 1.97 and 1.96 A, respectively. Compound 10 was active in cell culture, reversing resistance to the third generation cephalosporin ceftazidime in bacterial pathogens expressing AmpC. In contrast to beta-lactam-based inhibitors clavulanate and cefoxitin, compound 10 did not up-regulate beta-lactamase expression in cell culture but simply inhibited the enzyme expressed by the resistant bacteria. Its escape from this resistance mechanism derives from its dissimilarity to beta-lactam antibiotics.
PubMed: 15796528
DOI: 10.1021/ja042984o
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.96 Å)
Structure validation

229380

數據於2024-12-25公開中

PDB statisticsPDBj update infoContact PDBjnumon